Management of Non-Cirrhotic Portal Hypertension

Diagnostic Approach

The European Association for the Study of the Liver recommends that non-cirrhotic portal hypertension be diagnosed through liver biopsy to exclude cirrhosis and other causes of portal hypertension 3
Clinical signs of non-cirrhotic portal hypertension include splenomegaly, esophageal varices, ascites, increased hepatic venous pressure gradient, and portovenous collaterals 4
Doppler ultrasound is the first-line investigation for non-cirrhotic portal hypertension, with CT used for diagnostic confirmation and extension assessment 2
MR cholangiography should be performed in patients with persistent cholestasis or biliary tract abnormalities suggesting portal biliopathy 1

The American Association for the Study of Liver Diseases classifies non-cirrhotic portal hypertension into prehepatic, intrahepatic, and posthepatic causes 5
Common causes of non-cirrhotic portal hypertension include extrahepatic portal vein obstruction, idiopathic non-cirrhotic portal hypertension, Budd-Chiari syndrome, schistosomiasis, congenital hepatic fibrosis, and sarcoidosis 4
Extrahepatic portal vein obstruction is a common cause of non-cirrhotic portal hypertension 2
Idiopathic non-cirrhotic portal hypertension is a condition characterized by increased portal pressure in the absence of cirrhosis or other known causes of portal hypertension 4
Budd-Chiari syndrome is a rare condition characterized by thrombosis of the hepatic veins or the inferior vena cava 6

The American College of Gastroenterology recommends that management of portal hypertension follow the same guidelines established for cirrhosis 1, 3
Treatment should address both the underlying cause and portal hypertension-related complications 1, 3
Screen for portal vein thrombosis at least every 6 months in patients with idiopathic non-cirrhotic portal hypertension 3
Endoscopic therapy is effective in controlling acute variceal bleeding in 95% of idiopathic non-cirrhotic portal hypertension patients 3
Endoscopic band ligation is preferred over sclerotherapy for both acute bleeding and secondary prophylaxis 3
Non-selective beta-blockers should be used for primary and secondary prophylaxis of variceal bleeding, following the same approach as in cirrhosis 3

The American Association for the Study of Liver Diseases recommends that TIPS placement be considered for refractory variceal bleeding or ascites in non-cirrhotic portal hypertension 6
The meso-Rex bypass is an excellent option for children with accessible intrahepatic left portal vein 6
Liver transplantation should be considered for patients with progressive liver failure or unmanageable portal hypertension-related complications 3

Complications of portosystemic shunting such as hepatic encephalopathy are rare in non-cirrhotic portal hypertension patients due to preserved liver function 3
Monitor for development of portal vein thrombosis, especially in patients with idiopathic non-cirrhotic portal hypertension 3
Assess for cardiopulmonary complications such as hepatopulmonary syndrome, which may develop in patients with non-cirrhotic portal hypertension 6